Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672879 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01672879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01672879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
October 29, 2012
Completion date
January 3, 2017
Enrollment
259 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

liver fibrosis due to nash